129 related articles for article (PubMed ID: 21143511)
1. Clinical importance of the CYP2C19*17 variant allele for voriconazole.
Dolton MJ; McLachlan AJ
Br J Clin Pharmacol; 2011 Jan; 71(1):137-8. PubMed ID: 21143511
[No Abstract] [Full Text] [Related]
2. Roles of CYP3A4 and CYP2C19 in methyl hydroxylated and N-oxidized metabolite formation from voriconazole, a new anti-fungal agent, in human liver microsomes.
Murayama N; Imai N; Nakane T; Shimizu M; Yamazaki H
Biochem Pharmacol; 2007 Jun; 73(12):2020-6. PubMed ID: 17433262
[TBL] [Abstract][Full Text] [Related]
3. A case report of voriconazole therapy failure in a homozygous ultrarapid CYP2C19*17/*17 patient comedicated with carbamazepine.
Malingré MM; Godschalk PC; Klein SK
Br J Clin Pharmacol; 2012 Jul; 74(1):205-6. PubMed ID: 22122271
[No Abstract] [Full Text] [Related]
4. Modulators of very low voriconazole concentrations in routine therapeutic drug monitoring.
Hassan A; Burhenne J; Riedel KD; Weiss J; Mikus G; Haefeli WE; Czock D
Ther Drug Monit; 2011 Feb; 33(1):86-93. PubMed ID: 21192313
[TBL] [Abstract][Full Text] [Related]
5. CYP2C19 genotype is a major factor contributing to the highly variable pharmacokinetics of voriconazole.
Weiss J; Ten Hoevel MM; Burhenne J; Walter-Sack I; Hoffmann MM; Rengelshausen J; Haefeli WE; Mikus G
J Clin Pharmacol; 2009 Feb; 49(2):196-204. PubMed ID: 19033450
[TBL] [Abstract][Full Text] [Related]
6. Safety of voriconazole in a patient with CYP2C9*2/CYP2C9*2 genotype.
Geist MJ; Egerer G; Burhenne J; Mikus G
Antimicrob Agents Chemother; 2006 Sep; 50(9):3227-8. PubMed ID: 16940139
[No Abstract] [Full Text] [Related]
7. In vitro hepatic metabolism explains higher clearance of voriconazole in children versus adults: role of CYP2C19 and flavin-containing monooxygenase 3.
Yanni SB; Annaert PP; Augustijns P; Ibrahim JG; Benjamin DK; Thakker DR
Drug Metab Dispos; 2010 Jan; 38(1):25-31. PubMed ID: 19841059
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of voriconazole metabolism by chloramphenicol in an adolescent with central nervous system aspergillosis.
Hafner V; Albermann N; Haefeli WE; Ebinger F
Antimicrob Agents Chemother; 2008 Nov; 52(11):4172-4. PubMed ID: 18794387
[TBL] [Abstract][Full Text] [Related]
9. Potent cytochrome P450 2C19 genotype-related interaction between voriconazole and the cytochrome P450 3A4 inhibitor ritonavir.
Mikus G; Schöwel V; Drzewinska M; Rengelshausen J; Ding R; Riedel KD; Burhenne J; Weiss J; Thomsen T; Haefeli WE
Clin Pharmacol Ther; 2006 Aug; 80(2):126-35. PubMed ID: 16890574
[TBL] [Abstract][Full Text] [Related]
10. Pharmacogenomics of the triazole antifungal agent voriconazole.
Mikus G; Scholz IM; Weiss J
Pharmacogenomics; 2011 Jun; 12(6):861-72. PubMed ID: 21692616
[TBL] [Abstract][Full Text] [Related]
11. Effect of cytochrome P450 2C19 genotype on voriconazole exposure in cystic fibrosis lung transplant patients.
Berge M; Guillemain R; Trégouet DA; Amrein C; Boussaud V; Chevalier P; Lillo-Lelouet A; Le Beller C; Laurent-Puig P; Beaune PH; Billaud EM; Loriot MA
Eur J Clin Pharmacol; 2011 Mar; 67(3):253-60. PubMed ID: 21038076
[TBL] [Abstract][Full Text] [Related]
12. Prolonged half-life of voriconazole in a CYP2C19 homozygous poor metabolizer receiving vincristine chemotherapy: avoiding a serious adverse drug interaction.
Moriyama B; Falade-Nwulia O; Leung J; Penzak SR; JJingo C; Huang X; Henning SA; Wilson WH; Walsh TJ
Mycoses; 2011 Nov; 54(6):e877-9. PubMed ID: 21615537
[TBL] [Abstract][Full Text] [Related]
13. Correlation of CYP2C19 phenotype with voriconazole plasma concentration in children.
Narita A; Muramatsu H; Sakaguchi H; Doisaki S; Tanaka M; Hama A; Shimada A; Takahashi Y; Yoshida N; Matsumoto K; Kato K; Kudo K; Furukawa-Hibi Y; Yamada K; Kojima S
J Pediatr Hematol Oncol; 2013 Jul; 35(5):e219-23. PubMed ID: 23588332
[TBL] [Abstract][Full Text] [Related]
14. Voriconazole toxicity related to polymorphisms in CYP2C19.
Suan D; O'Connor K; Booth DR; Liddle C; Stewart GJ
Intern Med J; 2011 Apr; 41(4):364-5. PubMed ID: 21507170
[No Abstract] [Full Text] [Related]
15. Pharmacokinetics of intravenous voriconazole in obese patients: implications of CYP2C19 homozygous poor metabolizer genotype.
Moriyama B; Jarosinski PF; Figg WD; Henning SA; Danner RL; Penzak SR; Wayne AS; Walsh TJ
Pharmacotherapy; 2013 Mar; 33(3):e19-22. PubMed ID: 23400848
[TBL] [Abstract][Full Text] [Related]
16. Voriconazole therapeutic drug monitoring: focus on safety.
Pasqualotto AC; Xavier MO; Andreolla HF; Linden R
Expert Opin Drug Saf; 2010 Jan; 9(1):125-37. PubMed ID: 20021293
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics of voriconazole and cytochrome P450 2C19 genetic status.
Ikeda Y; Umemura K; Kondo K; Sekiguchi K; Miyoshi S; Nakashima M
Clin Pharmacol Ther; 2004 Jun; 75(6):587-8. PubMed ID: 15179414
[No Abstract] [Full Text] [Related]
18. Pharmacokinetics, metabolism and bioavailability of the triazole antifungal agent voriconazole in relation to CYP2C19 genotype.
Scholz I; Oberwittler H; Riedel KD; Burhenne J; Weiss J; Haefeli WE; Mikus G
Br J Clin Pharmacol; 2009 Dec; 68(6):906-15. PubMed ID: 20002085
[TBL] [Abstract][Full Text] [Related]
19. A case-report of unpredictable and massive voriconazole intoxication in a patient with extensive CYP2C19 and CYP2C9 polymorphisms.
Lemaitre F; Barbaz M; Scailteux LM; Uhel F; Tadié JM; Verdier MC; Bellissant E
Drug Metab Pharmacokinet; 2013; 28(5):439-41. PubMed ID: 23545593
[TBL] [Abstract][Full Text] [Related]
20. Hepatic drug interaction between tacrolimus and lansoprazole in a bone marrow transplant patient receiving voriconazole and harboring CYP2C19 and CYP3A5 heterozygous mutations.
Iwamoto T; Monma F; Fujieda A; Nakatani K; Katayama N; Okuda M
Clin Ther; 2011 Aug; 33(8):1077-80. PubMed ID: 21802143
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
